3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
14
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Basal Cell
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Tertiary Lymphoid Structures
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Microsatellite Instability
1
Male Urogenital Diseases
1
Locally Advanced Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Gastroesophageal Cancer
1
Interventions
padeliporfin
5
Lycopene
3
Vitamin E
2
Tea
2
Selenium
2
Cholecalciferol
2
relatlimab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
Therapeutics
1
Surveys and Questionnaires
1
Sugars
1
Nivolumab
1
Intraoperative Neurophysiological Monitoring
1
CP protocol
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Male Urogenital Diseases
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled